ARTERIOCYTE, INC.

Basic Information

7100 Euclid Ave.
CLEVELAND, OH, 44103-

Company Profile

n/a

Additional Details

Field Value
DUNS: 191821342
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. SMART Bandage for Monitoring Wound Perfusion

    Amount: $69,048.00

    ABSTRACT: Arteriocyte intends to develop and commercialize an innovative wound dressing. This SMART Bandage will incorporate an optical oxygen sensor and provide oxygen measurements of underlying wou ...

    SBIR Phase I 2014 Department of Defense Air Force
  2. Hematopoietic Reconstitution Using Ex Vivo Expanded Cord Blood CD34+ Cells

    Amount: $283,861.00

    DESCRIPTION (provided by applicant): Umbilical cord blood (UCB) provides unique advantages over bone marrow (BM) and mobilized peripheral blood (MPB) as a source of hematopoietic stem cells (HSCs) for ...

    SBIR Phase I 2012 Department of Health and Human Services
  3. RAPID, HIGH VOLUME PRODUCTION OF RETICULOCYTES FOR P. VIVAX MALARIA RESEARCH

    Amount: $219,995.00

    DESCRIPTION (provided by applicant): Malaria results from infection by one of five species of mosquito-borne parasite. Each year, these protists infect 350-500 million worldwide and kill over one mill ...

    SBIR Phase I 2011 Department of Health and Human Services
  4. Therapeutic Potential of Ex vivo expanded Human Cord Blood derived CD133+ cells i

    Amount: $2,196,210.00

    DESCRIPTION (provided by applicant): Critical Limb Ischemia (CLI) is a common problem that often results in major limb amputation. Circulating endothelial progenitor cells likely play a role in the pa ...

    SBIR Phase II 2010 Department of Health and Human Services
  5. A Novel Expansion of Primary Leukemia Stem Cells

    Amount: $304,943.00

    DESCRIPTION (provided by applicant): Arteriocyte's long-term objective is to develop a platform for ex vivo expansion of leukemic stem cell (LSC) based on cytokine-enriched medium and the company's pr ...

    SBIR Phase I 2010 Department of Health and Human Services
  6. Therapeutic Potential of Ex vivo expanded Human Cord Blood derived CD133+ cells i

    Amount: $281,794.00

    DESCRIPTION (provided by applicant): Critical Limb Ischemia (CLI) is a common problem that often results in major limb amputation. Circulating endothelial progenitor cells likely play a role in the pa ...

    SBIR Phase I 2008 Department of Health and Human Services
  7. CAN CD 133 CELLS PREVENT HYPOXIA DRIVEN RETINAL NEOVASCULARISATION IN A RODENT MO

    Amount: $310,645.00

    DESCRIPTION (provided by applicant): The clinical significance of ocular angiogenesis is enormous, due to the fact that in the western hemisphere, retinal neovascularization resulting from diabetic re ...

    STTR Phase I 2007 Department of Health and Human Services
  8. Marrow-Derived Stem Cells for Coronary Artery Ischemia

    Amount: $1,229,607.00

    DESCRIPTION (provided by applicant): Cardiovascular disease is the leading cause of morbidity and mortality in the United States, accounting for approximately 1 million deaths per year. The objective ...

    STTR Phase II 2006 Department of Health and Human Services
  9. Marrow-Derived Stem Cells for Coronary Artery Ischemia

    Amount: $142,954.00

    DESCRIPTION (provided by applicant): Cardiovascular disease is the leading cause of morbidity and mortality in the United States, accounting for approximately 1 million deaths per year. The objective ...

    STTR Phase I 2005 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government